Repligen Corporation

NasdaqGS RGEN

Repligen Corporation Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2024: USD -191.53 M

Repligen Corporation Net Cash Used For Investing Activities is USD -191.53 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -156.47% change year over year. Net cash used for investing activities is total cash inflows and outflows related to activities intended to generate future income and cash flows from investments.
  • Repligen Corporation Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -74.68 M, a 57.13% change year over year.
  • Repligen Corporation Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -174.20 M, a 45.08% change year over year.
  • Repligen Corporation Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -317.18 M, a -531.73% change year over year.
  • Repligen Corporation Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -50.21 M, a 75.35% change year over year.
Key data
Date Net Cash Used For Investing Activities Net Cash Used Provided By Financing Activities Dividends Paid Capital Expenditure
Market news
Loading...
SV Wall Street
NasdaqGS: RGEN

Repligen Corporation

Description

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Similar companies

HAE

Haemonetics Corporation

USD 69.05

-0.60%

NVST

Envista Holdings Corp

USD 20.52

-4.16%

ATR

AptarGroup, Inc.

USD 157.15

-0.62%

COO

The Cooper Companies, Inc.

USD 96.55

-1.58%

TFX

Teleflex Incorporated

USD 180.24

-1.42%

WST

West Pharmaceutical Services, Inc.

USD 341.55

-0.69%

BDX

Becton, Dickinson and Company

USD 247.60

-0.36%

RMD

ResMed Inc.

USD 236.18

-8.33%

MMSI

Merit Medical Systems, Inc.

USD 108.88

-1.28%

ICUI

ICU Medical, Inc.

USD 164.36

-0.93%

HOLX

Hologic, Inc.

USD 72.14

-0.04%

ANGO

AngioDynamics, Inc.

USD 11.41

-8.43%

ISRG

Intuitive Surgical, Inc.

USD 571.88

-1.43%

StockViz Staff

February 4, 2025

Any question? Send us an email